Zheng Kang

Dr. Zheng Kang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Frontiers in Microbiology
Verified
Journal Article
Open access
CHChen Hou
Chen Hou
YJYingqi Jin
Yingqi Jin
HWHua Wu
Hua Wu
PLPengyi Li
Pengyi Li
LLLongyun Liu
Longyun Liu
CWChuan Wang
Chuan Wang
Chlamydia is an obligate intracellular bacterium where most species are pathogenic and infectious, causing various infectious diseases and complications in humans and animals. Antibiotics are often recommended for the clinical treatment of chlamydial infections. However, extensive research has shown that antibiotics may not be sufficient to eliminate or inhibit infection entirely and have some potential risks, including antibiotic resistance. The impact of chlamydial infection and antibiotic misuse should not be underestimated in public health. This study explores the possibility of new therapeutic techniques, including a review of recent studies on preventing and suppressing chlamydial infection by non-antibiotic compounds.

19 March 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JJJing Jiang
Jing Jiang
LXLinglan Xu
Linglan Xu
XWXuefeng Wang
Xuefeng Wang
MWMing Wang
Ming Wang
YCYoude Cao
Youde Cao
XWXian Wu
Xian Wu
Background: Treponema pallidum, the causative spirochete of syphilis, is primarily transmitted through sexual contact and has emerged as a significant global health concern. To address this issue, enhancing diagnostic capabilities, strengthening public health interventions, and developing a safe and effective vaccine are critical strategies.Objective: This study employed an immunoinformatics approach to design a vaccine with high immunogenic potential, targeting the heat shock proteins of T. pallidum.Methods: Based on heat shock proteins of T. pallidum, we predicted B-cell, CTL, and HTL epitopes and all the selected epitopes were linked to construct a multi-epitope vaccine. Antigenicity, toxicity, and allergenicity of epitopes were checked by VaxiJen 2.0, AllerTOP v2.0, and ToxinPred servers. After constructing the multi-epitope vaccine, we subsequently predicted its secondary and tertiary protein structures. After refining and validating the modeled structure, we utilized advanced computational approaches, including molecular docking and dynamic simulations, to evaluate the binding affinity, compatibility, and stability of the vaccine-adjuvant complexes. Eventually, in silico cloning was conducted to optimize protein expression and production.Results: The multi-epitope subunit vaccine we developed was constructed by seven cytotoxic T lymphocyte epitopes, five helper T lymphocyte epitopes, four B cell epitopes, and adjuvant β-defensin. An adjuvant was used to enhance immune responses, all of which were linked to one another using GPGPG, AAY, and KK linkers, respectively. The population coverage of the designed vaccine was 94.41% worldwide. Molecular docking and MD simulations indicated strong binding interactions with TLR1/2, TLR-2 and TLR-4 in a stable vaccine-receptor complex. The final designed vaccine, composed of 502 amino acids, theoretically exhibits high antigenicity and immunity, capable of inducing both humoral and cellular immune responses.Conclusion: The vaccine developed in this study theoretically represents a safe and potent multi-epitope prophylactic strategy against T. pallidum, subject to further experimental validation to ascertain its actual protective efficacy.

16 October 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
WLWeiwei Li
Weiwei Li
WYWei Yuan
Wei Yuan
SHShaobin Huang
Shaobin Huang
LZLin Zou
Lin Zou
ZKZheng Kang
Zheng Kang
DXDongde Xie
Dongde Xie

22 October 2023 in Current Problems in Cardiology
Verified
Journal Article
Closed access
GZGuang-Gui Zeng
Guang-Gui Zeng
QLQiong Lei
Qiong Lei
WJWan-Li Jiang
Wan-Li Jiang
XZXing-Xing Zhang
Xing-Xing Zhang
LNLiluo Nie
Liluo Nie
ZKZheng Kang
Zheng Kang

4 October 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
TJTang Jun
Tang Jun
LZLiu Zhimin
Liu Zhimin
DXDeng Xi
Deng Xi
WHWu Hua
Wu Hua
SHShen Huilong
Shen Huilong
XQxie qinghua
xie qinghua

Verified
Journal Article
Open access
PDF file
CWChuan Wang
Chuan Wang
YJYingqi Jin
Yingqi Jin
JWJiewen Wang
Jiewen Wang
ZKZheng Kang
Zheng Kang
ALAihua Lei
Aihua Lei
YWYimou Wu
Yimou Wu
Chlamydia psittaci (C. psittaci), a zoonotic pathogen, poses a potential threat to public health security and the development of animal husbandry. Vaccine-based preventative measures for infectious diseases have a promising landscape. DNA vaccines, with many advantages, have become one of the dominant candidate strategies in preventing and controlling the chlamydial infection. Our previous study showed that CPSIT_p7 protein is an effective candidate for a vaccine against C. psittaci. Thus, this study evaluated the protective immunity of pcDNA3.1(+)/CPSIT_p7 against C. psittaci infection in BALB/c mice. We found that pcDNA3.1(+)/CPSIT_p7 can induce strong humoral and cellular immune responses. The IFN-γ and IL-6 levels in the infected lungs of mice immunized with pcDNA3.1(+)/CPSIT_p7 reduced substantially. In addition, the pcDNA3.1(+)/CPSIT_p7 vaccine diminished pulmonary pathological lesions and reduced the C. psittaci load in the lungs of infected mice. It is worth noting that pcDNA3.1(+)/CPSIT_p7 suppressed C. psittaci dissemination in BALB/c mice. In a word, these results demonstrate that the pcDNA3.1(+)/CPSIT_p7 DNA vaccine has good immunogenicity and immunity protection effectiveness against C. psittaci infection in BALB/c mice, especially pulmonary infection, and provides essential practical experience and insights for the development of a DNA vaccine against chlamydial infection.